Topographic pharmaco‐EEG mapping of increasing doses of buspirone and its comparison with diazepam
The DOI matches its Crossref record.
Abstract
It has been argued that representative drugs of the main psychopharmacological classes induce similar pharmaco‐EEG changes within groups but different changes between groups. The aim of this double‐blind, cross‐over, placebocontrolled study was to evaluate the effects of single oral doses of buspirone (BUS) 5, 15 and 30 mg in 15 healthy young subjects of both sexes on topographic maps of quantiative pharmaco‐EEG, using diazepam (DZP) 10 mg as reference compound. Sixteen lead recordings of three‐minute vigilance‐controlled EEG (V‐EEG) and four‐minute resting EEG (R‐EEG) were assessed at 0, 1, 2, 4, 6 and 8 hours after drug intake. EOG activity (vertical and horizontal) was also recorded in order to minimize ocular artifacts before applying an automatic artifact rejection method. MANOVA/Hotelling T 2 maps (multivariate analysis) showed a highly significant differentiation of DZP from placebo from the 1 st until the 8th hour all over the brain. After BUS a clear dose‐response was observed with effects being greater and longer lasting with increasing doses, the highest showing a peak effect in the 2nd hour which lasted until the 4th hour, mostly in central regions. Maps of drug‐induced pharmaco‐EEG changes as compared to placebo‐induced alterations (univariate analysis) demonstrated typical ‘anxiolytic pharmaco‐EEG patterns’ after DZP, characterized by a decrease of total power, attenuation of alpha activity and augmentation of beta activity, as well as by an increase of the centroid and centroid deviation of the total activity. Furthermore, a decrease of the centroid of the combined delta‐theta activity and an increase of the centroid of alpha activity was seen. In contrast, BUS produced an increase of theta activity with an acceleration of the centroid of the combined delta‐theta activity, no modification of alpha activity but a slowing down of its centroid and a tendency to reduce beta activity. The centroid of the total activity was also decreased. Although both compounds have proven their ability to reduce anxiety in patients, their different neurophysiological profiles suggest different neurobiological mechanisms of action after acute administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Allen, A. P., Hutch, W., Borre, Y. E., Kennedy, P. J., Temko, A., Boylan, G., Murphy, E., Cryan, J. F., Dinan, T. G., & Clarke, G. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.191 · Cited by 513
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Self-citationRiba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01609.x · Cited by 125
Self-citationCiraulo, D. A., Barnhill, J. G., Ciraulo, A. M., Sarid‐Segal, O., Knapp, C., Greenblatt, D. J., & Shader, R. I. (1997) · The Journal of Clinical Pharmacology · doi:10.1177/009127009703700111 · Cited by 28
Önnestam, K., Nilsson, B., Rother, M., Rein-Hedin, E., Bylund, J., Anderer, P., Kemethofer, M., Halldin, M. M., Sandin, J., & Segerdahl, M. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.89 · Cited by 10
“It is also similar to the EEG profile reported for buspirone (a partial serotonin receptor 1A (5-HT1A) agonist and dopamine D2/D3 receptor antagonist) in healthy subjects (49, 50).”
ResultSelf-citation
Metadata
- Authors
- Barbanoj, M. J., Anderer, P., Antonijoan, R. M., Torrent, J., Saletu, B., & Jané, F.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 1994-03
- Volume
- 9
- Issue
- 2
- Pages
- 101-109
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2053700311
- Cited by
- 25
- References
- 0
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.